You request, we deliver. The only platform shaped by an open trader community.
Got a question or a feature you wish existed? Drop it in our Telegram community, the Stolo team is right there reading every message.
The Nifty Healthcare Index is NSE’s dedicated benchmark for India’s listed healthcare businesses: the pharmaceutical manufacturers, hospital chains, diagnostics companies, and biotech firms that make up the sector. If you want to know what it tracks, how it’s built, which stocks carry the most weight, and whether it deserves a place in your portfolio or watchlist, this guide covers the mechanics end to end.
Healthcare doesn’t behave like the rest of the market. Part of the sector, hospital chains and branded generics, offers fairly steady, defensive demand. Another part, biotech and export-heavy pharma, can swing hard on a single regulatory approval or patent ruling. Alongside broad benchmarks like the Nifty 50, sector-specific stock market indices like this one let you isolate that behavior instead of reading it as noise inside a blended number. Stolo’s guide to sectoral indices is a useful primer if sector-level benchmarks are new to you.
By the end of this guide, you’ll know how the Nifty Healthcare Index is calculated, which companies currently drive it, how it compares to Nifty Pharma and Nifty 50, and the risks worth weighing before you use it as an investment thesis.
The Nifty Healthcare Index is a sectoral benchmark designed by NSE Indices to measure the collective performance of healthcare companies listed on the National Stock Exchange. It sits as a subset of the broader Nifty 500, pulling out just the healthcare names for anyone who wants to track the sector on its own rather than reading it as one line inside a 500-stock index.
The index is built to serve a few specific purposes:
It currently includes up to 20 healthcare-related companies, spanning pharmaceutical manufacturers, biotechnology and specialty pharma firms, hospital chains, and diagnostic service providers. That range matters: it’s broader than a pure pharma play, because it captures the service side of healthcare (hospitals, diagnostics) alongside the manufacturing side (drugs, formulations, active pharmaceutical ingredients).
Definition: Free-float market capitalisation. This is the method NSE uses to weight every stock in the Nifty family, including this index. Only the shares actually available for public trading count toward a company’s weight, promoter holdings, government stakes, and locked-in shares are excluded. A company with a large total market cap but heavy promoter holding will carry less index weight than the headline number suggests.
The methodology follows the same rulebook as every other sectoral index in the Nifty family.
Free-float weighting. Only publicly tradable shares count. Larger companies by free-float value carry proportionally more influence over the index’s daily move.
Base date and rebalancing. Like every Nifty index, this one runs from a fixed base date and base value, and NSE Indices reviews and rebalances the composition on a semi-annual basis. Cut-off dates determine which companies qualify going into each rebalancing cycle.
Eligibility rules. To stay in (or enter) the index, a company needs to clear NSE’s thresholds for listing status, trading liquidity, and free-float market capitalisation, and it needs to be classified within the healthcare industry rather than a conglomerate with an unrelated core business.
The exact rulebook, cut-off dates, and eligibility criteria are published by NSE Indices and updated with each factsheet, so if you need the precise current methodology document, that’s the primary source to check rather than relying on secondary summaries.
As of the most recent factsheet (September 2025), the index’s top constituents include names most traders will already recognise:
Rounding out the up-to-20-stock list are names including Fortis Healthcare, Lupin, Torrent Pharmaceuticals, and Laurus Labs, among others.
Broadly, the constituents split into two groups: pharmaceutical manufacturers (Sun Pharma, Cipla, Dr Reddy’s, Lupin, Torrent Pharmaceuticals, Divi’s Laboratories) that make formulations, generics, and active pharmaceutical ingredients, often for export markets, and healthcare service providers (Apollo Hospitals, Max Healthcare, Fortis Healthcare) that run hospital chains and diagnostic networks serving the domestic market. That split is exactly why the index doesn’t move as a single block, the two groups respond to different triggers.
Note: Weightage and composition shift with every semi-annual rebalancing, so treat the list above as a snapshot rather than a fixed order. NSE Indices publishes the current factsheet and constituent weights for anyone who wants the live numbers.
This is one of the most common points of confusion, and it’s a fair one, since the two indices overlap heavily. Pharmaceutical manufacturers like Sun Pharma, Cipla, Dr Reddy’s, and Lupin sit in both baskets.
The difference is scope. Nifty Pharma is built purely from drug manufacturers, formulation companies, and pharma-adjacent businesses. The Nifty Healthcare Index casts a wider net: it adds hospital chains and diagnostics providers, Apollo Hospitals and Max Healthcare being the clearest examples, that Nifty Pharma doesn’t include at all.
In practice, that makes Nifty Healthcare a somewhat more diversified read on the sector. A patent ruling or a USFDA warning letter that hits export-oriented pharma names will move Nifty Pharma harder than it moves Nifty Healthcare, because the hospital and diagnostics constituents in the healthcare index aren’t exposed to that specific risk. If your view is specifically on Indian pharma manufacturing and exports, Nifty Pharma is the tighter instrument. If your view is on India’s healthcare industry broadly, including the domestic hospital and diagnostics buildout, the Nifty Healthcare Index is the closer match.
Sector indices don’t move in lockstep with the broad market, and healthcare’s relationship with the Nifty 50 reflects the two different characters inside the sector.
The hospital and branded-generics side leans defensive: healthcare demand doesn’t disappear in a slowdown the way discretionary spending does, and that shows up as more stable earnings and, in some constituents, steady dividend yields. The pharma and biotech side can be considerably more volatile, since a single regulatory approval, patent expiry, or import-alert from a foreign regulator can reprice a stock (and by extension the index) quickly.
NSE’s official factsheet is the best source for the summary statistics that quantify this: standard deviation, correlation to Nifty 50, and historical returns across multiple time frames. In the most recent factsheet, the Nifty Healthcare Index showed a moderately high correlation with Nifty 50, around 0.74, meaning it tends to move with the broader market on most days while still carrying enough sector-specific divergence to matter for diversification. For daily index values and total return series if you want to compute your own return windows, the NSE Indices historical data pages and market data providers like Economic Times Markets publish the raw series.
A few structural reasons keep this index on people’s watchlists beyond just curiosity about the sector.
It’s a clean benchmark. Fund managers running healthcare-focused mutual funds or PMS strategies measure themselves against this index rather than the broad market, since comparing a sector fund to Nifty 50 tells you little about whether the manager actually picked good healthcare stocks.
It offers diversified sector exposure. Rather than betting on one hospital chain or one pharma exporter, the index spreads that bet across roughly 20 companies weighted by free float, which reduces single-stock risk while keeping the sector thesis intact.
Its correlation behavior is genuinely useful. Because healthcare doesn’t always move in step with the broader market, understanding sector rotation helps explain why healthcare stocks sometimes lead when cyclical sectors are struggling, and lag when the market is in full risk-on mode.
The demand backdrop has real tailwinds. Rising healthcare spending as household incomes grow, government programs like Ayushman Bharat expanding coverage, India’s growing position as a medical tourism destination, and the rise of telemedicine and digital diagnostics are all structural shifts rather than short-term trends. None of that guarantees returns, and regulatory risk and competition remain real constraints, but the demand-side fundamentals for the sector are grounded in more than sentiment.
The defensive reputation healthcare carries doesn’t mean the index is risk-free. A few sector-specific factors are worth understanding before you treat it as a core holding or a trading instrument.
Regulatory and pricing risk. India’s drug price control regime (through the NPPA) caps prices on certain essential medicines, which directly affects margins for domestic-facing pharma names. Export-oriented manufacturers carry a separate regulatory exposure: a USFDA warning letter or import alert on a manufacturing facility can halt shipments and hit revenue with little warning.
Patent cliffs and generic competition. A meaningful share of Indian pharma revenue comes from generics sold into regulated markets like the US. When patents on branded drugs expire, it can open opportunity, but the same dynamic works in reverse when a company’s own key products face generic competition.
Currency exposure. Export-heavy constituents earn a real share of revenue in dollars or euros, so rupee movements flow through to reported earnings in ways that purely domestic-facing companies don’t experience.
Concentration risk. Like most sectoral indices, a handful of large constituents drive most of the index’s move on any given day. That can mask what’s happening in the smaller names inside the same basket.
Policy dependency. Government-driven demand, Ayushman Bharat funding, PLI scheme continuity for pharma manufacturing, is a genuine tailwind, but it also means the sector’s growth story is partly tied to policy continuity rather than market forces alone.
None of this makes the index unusable. It just means the same qualities that make healthcare defensive in a downturn (steady demand, insulated from consumer discretionary swings) coexist with sector-specific risks that a broad index like Nifty 50 doesn’t carry.
There are two practical routes.
Index funds and ETFs. Several fund houses run passive products that track the Nifty Healthcare Index, giving you the full basket in roughly the same proportions as the index weighting, in a single trade. This is the lower-effort route if your goal is sector exposure rather than picking individual winners.
Individual constituent stocks. Buying the underlying companies directly, Sun Pharma, Cipla, Apollo Hospitals, and the rest, gives you more control but requires understanding each business rather than the sector as a whole. This route suits investors who have a view on specific companies rather than the sector broadly.
One important caveat: the Nifty Healthcare Index itself doesn’t currently have its own listed futures and options contracts on the NSE, unlike Nifty 50 or Nifty Bank. If you’re looking for derivatives exposure to the sector, the practical route is trading options on the individual constituents instead, Sun Pharma, Cipla, Dr Reddy’s, and Apollo Hospitals all carry active F&O markets of their own. Stolo’s option chain analysis for indices and stocks covers exactly this: live open interest and positioning data on individual healthcare constituents, the same read professional desks use before taking a position. If you’d rather see the whole sector at a glance first, Stolo’s market heatmap shows which healthcare stocks are leading or lagging in real time, so you’re not inferring sector strength after the fact.
The Nifty Healthcare Index is a genuinely useful benchmark for anyone who wants structured exposure to India’s healthcare sector, whether that’s through a passive fund, direct stock picks, or simply as a reference point for how the sector is doing relative to the broader market. It bundles two different businesses, defensive hospital and branded-generics demand, and higher-beta pharma and biotech, into one number, which is exactly why understanding the split matters more than watching the headline figure alone.
Whether it earns a place in your portfolio comes down to your own time horizon and risk tolerance. If you want long-term exposure to a sector with real structural tailwinds, healthcare spending growth, government coverage expansion, medical tourism, it’s worth serious consideration. If you’re trading it, remember you’re really trading a basket of constituent stocks rather than a single liquid derivative, so read the individual names as closely as the index headline.
What is the Nifty Healthcare Index?
The Nifty Healthcare Index is an NSE sectoral benchmark that tracks the performance of healthcare companies listed on the National Stock Exchange, including pharmaceutical manufacturers, hospital chains, diagnostics providers, and biotech firms. It’s a subset of the broader Nifty 500 index.
Which stocks are included in the Nifty Healthcare Index?
The index includes up to 20 healthcare companies. As of the most recent factsheet, top constituents include Sun Pharmaceutical Industries, Cipla, Max Healthcare Institute, Divi’s Laboratories, Apollo Hospitals Enterprise, and Dr Reddy’s Laboratories, along with names like Fortis Healthcare, Lupin, Torrent Pharmaceuticals, and Laurus Labs. Because NSE rebalances the index twice a year, it’s worth checking the current factsheet for the exact live list.
How is the Nifty Healthcare Index calculated?
It uses the free-float market capitalisation method, where only publicly tradable shares (excluding promoter and locked-in holdings) count toward a company’s weight. The index runs from a fixed base date and base value and is rebalanced by NSE Indices every six months.
What is the difference between the Nifty Healthcare Index and the Nifty Pharma Index?
Nifty Pharma includes only pharmaceutical manufacturers and formulation companies. The Nifty Healthcare Index is broader: it includes those same pharma names plus hospital chains and diagnostics providers like Apollo Hospitals and Max Healthcare, which Nifty Pharma excludes entirely. That makes Nifty Healthcare a more diversified read on the sector as a whole.
Can I invest directly in the Nifty Healthcare Index?
You can’t buy the index itself, but you can get the same exposure through index funds or ETFs built to track it, which hold the constituent stocks in roughly the same proportions as the index. Alternatively, you can buy the individual constituent stocks directly.
Can I trade futures and options on the Nifty Healthcare Index?
No, not on the index itself. Unlike Nifty 50 or Nifty Bank, the Nifty Healthcare Index doesn’t currently have its own listed futures and options contracts on the NSE. Traders looking for derivatives exposure to the sector typically trade options on individual constituents such as Sun Pharma, Cipla, Dr Reddy’s, or Apollo Hospitals instead.
What is the highest-weighted stock in the Nifty Healthcare Index?
The highest-weighted stock is typically one of the larger pharmaceutical names in the basket, such as Sun Pharmaceutical Industries or Dr Reddy’s Laboratories, though the exact ranking shifts with each semi-annual rebalancing as free-float market caps change. NSE’s live factsheet is the authoritative source for the current weightage order.
How often is the Nifty Healthcare Index rebalanced?
NSE Indices reviews and rebalances the index every six months, adding or removing companies based on liquidity, trading activity, and free-float market capitalisation, so it continues to reflect the sector’s most significant, actively traded names.
Is the Nifty Healthcare Index a good long-term investment?
That depends on your risk tolerance and time horizon. The sector has real structural tailwinds, rising healthcare spending, government coverage expansion, medical tourism, and health-tech adoption, but it also carries regulatory, currency, and concentration risks that a diversified index like Nifty 50 doesn’t. It suits investors who specifically want sector exposure rather than a core market holding.
Markets aren’t just about individual stocks, they’re about the big groupings that tie them together. From heavyweight benchmarks to focused sector champs, these indices tell different stories about the market: Nifty 50 | BSE Sensex | BSE 100 | FINNIFTY | Nifty Bank | Nifty Next 50 | Nifty 100 | Nifty Midcap 150 | Nifty Smallcap 250 | Nifty Pharma Index | Nifty IT Index | Nifty Auto Index | Nifty FMCG | Nifty Metal Index | Nifty Realty Index | Nifty Media | Nifty Energy | Nifty 500
Got a question or a feature you wish existed? Drop it in our Telegram community, the Stolo team is right there reading every message.